Bavarian Nordic A/S (BAVA.CO)
DKK 198.95
(2.82%)
DKK 198.95
(2.82%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 19.23 DKK | 490.06% |
| 2022 | -4.93 DKK | 33.11% |
| 2021 | -7.37 DKK | -243.66% |
| 2020 | 5.13 DKK | 160.35% |
| 2019 | -8.50 DKK | 4.28% |
| 2018 | -8.88 DKK | -296.9% |
| 2017 | 4.51 DKK | 470.89% |
| 2016 | 0.79 DKK | -52.41% |
| 2015 | 1.66 DKK | 110.13% |
| 2014 | 0.79 DKK | 155.63% |
| 2013 | -1.42 DKK | 80.49% |
| 2012 | -7.28 DKK | 41.2% |
| 2011 | -12.38 DKK | 68.43% |
| 2010 | -39.21 DKK | -26.24% |
| 2009 | -31.06 DKK | -117.35% |
| 2008 | -14.29 DKK | -225.51% |
| 2007 | -4.39 DKK | 65.16% |
| 2006 | -12.60 DKK | -45.66% |
| 2005 | -8.65 DKK | -53.37% |
| 2004 | -5.64 DKK | -137.5% |
| 2003 | 15.04 DKK | 89.66% |
| 2002 | 7.93 DKK | 158.52% |
| 2001 | -13.55 DKK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 3.34 DKK | 324.49% |
| 2024 Q1 | -1.47 DKK | -112.51% |
| 2023 Q2 | 6.90 DKK | 42.86% |
| 2023 FY | - DKK | 490.06% |
| 2023 Q3 | -4.37 DKK | -163.33% |
| 2023 Q4 | 11.75 DKK | 368.88% |
| 2023 Q1 | 4.83 DKK | 127.83% |
| 2022 FY | - DKK | 33.11% |
| 2022 Q3 | 0.20 DKK | 105.88% |
| 2022 Q1 | -3.90 DKK | -139.26% |
| 2022 Q2 | -3.40 DKK | 12.82% |
| 2022 Q4 | 2.12 DKK | 960.0% |
| 2021 FY | - DKK | -243.66% |
| 2021 Q1 | -2.20 DKK | 69.06% |
| 2021 Q2 | -2.40 DKK | -9.09% |
| 2021 Q3 | -1.30 DKK | 45.83% |
| 2021 Q4 | -1.63 DKK | -25.38% |
| 2020 Q2 | 2.20 DKK | -82.54% |
| 2020 Q3 | 0.50 DKK | -77.27% |
| 2020 Q4 | -7.11 DKK | -1522.0% |
| 2020 FY | - DKK | 160.35% |
| 2020 Q1 | 12.60 DKK | 1215.04% |
| 2019 Q1 | -3.10 DKK | -22.53% |
| 2019 Q2 | -3.20 DKK | -3.23% |
| 2019 Q3 | -3.10 DKK | 3.13% |
| 2019 FY | - DKK | 4.28% |
| 2019 Q4 | -1.13 DKK | 63.55% |
| 2018 Q2 | -2.69 DKK | 40.35% |
| 2018 FY | - DKK | -296.9% |
| 2018 Q1 | -4.51 DKK | 2.38% |
| 2018 Q4 | -2.53 DKK | -420.25% |
| 2018 Q3 | 0.79 DKK | 129.37% |
| 2017 FY | - DKK | 470.89% |
| 2017 Q3 | 8.15 DKK | 584.87% |
| 2017 Q2 | 1.19 DKK | 843.75% |
| 2017 Q1 | -0.16 DKK | -107.02% |
| 2017 Q4 | -4.62 DKK | -156.69% |
| 2016 Q4 | 2.28 DKK | -12.64% |
| 2016 Q2 | -0.71 DKK | 80.49% |
| 2016 Q1 | -3.64 DKK | -5700.0% |
| 2016 FY | - DKK | -52.41% |
| 2016 Q3 | 2.61 DKK | 467.61% |
| 2015 FY | - DKK | 110.13% |
| 2015 Q4 | 0.06 DKK | 104.58% |
| 2015 Q3 | -1.42 DKK | -181.61% |
| 2015 Q2 | 1.74 DKK | 37.01% |
| 2015 Q1 | 1.27 DKK | -53.48% |
| 2014 Q2 | -1.66 DKK | -4660.44% |
| 2014 Q4 | 2.73 DKK | 596.36% |
| 2014 Q3 | -0.55 DKK | 66.87% |
| 2014 FY | - DKK | 155.63% |
| 2014 Q1 | 0.04 DKK | 104.49% |
| 2013 Q3 | 0.55 DKK | 443.75% |
| 2013 Q4 | -0.81 DKK | -247.27% |
| 2013 FY | - DKK | 80.49% |
| 2013 Q1 | -1.03 DKK | 45.79% |
| 2013 Q2 | -0.16 DKK | 84.47% |
| 2012 FY | - DKK | 41.2% |
| 2012 Q4 | -1.90 DKK | -401.59% |
| 2012 Q3 | 0.63 DKK | 112.26% |
| 2012 Q2 | -5.14 DKK | -490.8% |
| 2012 Q1 | -0.87 DKK | 39.58% |
| 2011 Q4 | -1.44 DKK | 4.0% |
| 2011 FY | - DKK | 68.43% |
| 2011 Q1 | -4.28 DKK | 65.92% |
| 2011 Q2 | -3.56 DKK | 16.82% |
| 2011 Q3 | -1.50 DKK | 57.87% |
| 2010 Q2 | -3.22 DKK | 40.37% |
| 2010 Q1 | -5.40 DKK | 49.49% |
| 2010 Q4 | -12.56 DKK | -49.52% |
| 2010 FY | - DKK | -26.24% |
| 2010 Q3 | -8.40 DKK | -160.87% |
| 2009 Q2 | -6.50 DKK | -25.0% |
| 2009 Q1 | -5.20 DKK | 0.0% |
| 2009 FY | - DKK | -117.35% |
| 2009 Q4 | -10.69 DKK | -116.4% |
| 2009 Q3 | -4.94 DKK | 24.0% |
| 2008 FY | - DKK | -225.51% |
| 2007 FY | - DKK | 65.16% |
| 2006 FY | - DKK | -45.66% |
| 2005 FY | - DKK | -53.37% |
| 2004 FY | - DKK | -137.5% |
| 2003 FY | - DKK | 89.66% |
| 2002 FY | - DKK | 158.52% |
| 2001 FY | - DKK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ALK-Abelló A/S | 2.20 DKK | -774.091% |
| Genmab A/S | 66.64 DKK | 71.143% |
| Gubra A/S | -2.93 DKK | 756.314% |
| Novo Nordisk A/S | 18.67 DKK | -2.999% |
| Orphazyme A/S | -0.74 DKK | 2698.649% |
| Pharma Equity Group A/S | -0.02 DKK | 84442.105% |
| Zealand Pharma A/S | -12.44 DKK | 254.582% |